MCID: MLT113
MIFTS: 45

Multicentric Castleman Disease

Categories: Rare diseases, Immune diseases

Aliases & Classifications for Multicentric Castleman Disease

MalaCards integrated aliases for Multicentric Castleman Disease:

Name: Multicentric Castleman Disease 50
Multicentric Plasma Cell Variant of Castleman's Disease 50
Plasmablastic Multicentric Castleman Disease 50
Idiopathic Multicentric Castleman's Disease 50
Multicentric Giant Lymph Node Hyperplasia 50
Multi-Centric Castleman's Disease 69
Pmcd 50
Mcd 50

Classifications:



Summaries for Multicentric Castleman Disease

NIH Rare Diseases : 50 multicentric castleman disease (mcd) is a rare condition that affects the lymph nodes and related tissues. it is a form of castleman disease that is "systemic" and affects multiple sets of lymph nodes and other tissues throughout the body (as opposed to unicentric castleman disease which has more "localized" effects). the signs and symptoms of mcd are often nonspecific and blamed on other, more common conditions. they can vary but may include fever; weight loss; fatigue; night sweats; enlarged lymph nodes; nausea and vomiting; and an enlarged liver or spleen. the eact underlying cause is unknown. treatment may involve immunotherapy, chemotherapy, corticosteroid medications and/or anti-viral drugs. last updated: 6/25/2015

MalaCards based summary : Multicentric Castleman Disease, also known as multicentric plasma cell variant of castleman's disease, is related to lymphoma and systemic lupus erythematosus, and has symptoms including fever An important gene associated with Multicentric Castleman Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Allograft rejection and Th17 cell differentiation. The drugs Ganciclovir and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and spleen, and related phenotypes are hematopoietic system and immune system

Related Diseases for Multicentric Castleman Disease

Diseases related to Multicentric Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
id Related Disease Score Top Affiliating Genes
1 lymphoma 30.4 IFNG IL10 IL5 IL6
2 systemic lupus erythematosus 29.0 CRP F3 IFNG IL10 IL6
3 kaposi sarcoma 11.9
4 malonyl-coa decarboxylase deficiency 11.7
5 multiple carboxylase deficiency 11.6
6 macular corneal dystrophy 11.6
7 metaphyseal chondrodysplasia, schmid type 11.5
8 castleman disease 11.5
9 human herpesvirus 8 11.4
10 unicentric castleman disease 11.0
11 collagenopathy type 2 alpha 1 10.9 CRP IL6
12 crystal arthropathies 10.8 CRP IL6
13 aortic arch interruption 10.8 IL5 IL6
14 common peroneal nerve lesion 10.8 IL5 IL6
15 shoulder impingement syndrome 10.8 CRP IL6
16 peroneal nerve paralysis 10.8 IL10 IL6
17 brachydactyly-distal symphalangism syndrome 10.8 CRP IL6
18 drug rash with eosinophilia and systemic symptoms 10.7 IL10 IL6
19 epstein-barr virus hepatitis 10.7 CRP IL6
20 cataract congenital autosomal dominant 10.7 CRP IL6 KRT15
21 breast papillary carcinoma 10.7 CRP IL10 IL6
22 solitary cyst of breast 10.7 CRP IL5
23 plummer's disease 10.7 CRP IL10 IL6
24 residual stage corticosteroid-induced glaucoma 10.6 CRP IL10 IL6
25 x-linked dominant intellectual disability-epilepsy syndrome 10.6 CRP IL6
26 atrophy of prostate 10.6 CRP IL10 IL6
27 choroiditis 10.6 CRP IL10 IL6
28 endocervical type cervical mucinous adenocarcinoma 10.6 CRP IL10 IL6
29 queensland tick typhus 10.6 CRP IL5 IL6
30 myofascial pain syndrome 10.6 IL10 IL5 IL6
31 mixed mineral dust pneumoconiosis 10.6 CRP IL10 IL6
32 infancy electroclinical syndrome 10.6 IL10 IL6
33 diamond-blackfan anemia 1 10.6 CRP IL10 IL6
34 cryoglobulinemia 10.6 CRP IL10 IL6
35 acquired von willebrand syndrome 10.6 F3 F8
36 erythema elevatum diutinum 10.6 CRP IL6
37 fragile x syndrome type 2 10.6 F3 F8
38 chronic diarrhea due to guanylate cyclase 2c overactivity 10.5 CRP F3 IL6
39 eye accommodation disease 10.5 IFNG IL10
40 midline cystocele 10.5 CRP F3
41 vulvovaginal gingival syndrome 10.5 BCL6 PAX5
42 parasitic helminthiasis infectious disease 10.5 CRP F3 IL6
43 gastroschisis 10.5 IFNG IL5
44 ethmoid sinus adenocarcinoma 10.5 IL10 IL6
45 crustacean allergy 10.5 IL10 IL5
46 acquired pure red cell aplasia 10.5 F3 F8
47 von willibrand disease, type 3 10.5 F3 F8
48 megaloblastic anemia 10.5 CRP F3 IL10
49 granulomatous hepatitis 10.5 CRP F3 IL6
50 angina pectoris 10.5 CRP F3 IL6

Graphical network of the top 20 diseases related to Multicentric Castleman Disease:



Diseases related to Multicentric Castleman Disease

Symptoms & Phenotypes for Multicentric Castleman Disease

UMLS symptoms related to Multicentric Castleman Disease:


fever

MGI Mouse Phenotypes related to Multicentric Castleman Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.11 BCL6 IL10 F3 IL21 IL5 F8
2 immune system MP:0005387 10.1 BCL6 IL10 CRP F3 IL21 IL5
3 cardiovascular system MP:0005385 10.01 ABCB1 IFNG BCL6 CRP IL10 F3
4 liver/biliary system MP:0005370 9.8 BCL6 IL10 IL5 ID1 IL6 ABCB1
5 neoplasm MP:0002006 9.7 IL10 F3 IL5 ID1 IL6 IFNG
6 reproductive system MP:0005389 9.56 IFNG BCL6 IL10 F8 IL5 ID1
7 respiratory system MP:0005388 9.17 IFNG BCL6 IL10 F3 IL5 ID1

Drugs & Therapeutics for Multicentric Castleman Disease

Drugs for Multicentric Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganciclovir Approved, Investigational Phase 4,Phase 2 82410-32-0 3454
2
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
3 Anti-Infective Agents Phase 4,Phase 2,Phase 1
4 Antiviral Agents Phase 4,Phase 2
5 Ganciclovir triphosphate Phase 4,Phase 2
6 Siltuximab Approved Phase 2,Phase 1,Early Phase 1 541502-14-1
7
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
9
Zidovudine Approved Phase 2 30516-87-1 35370
10
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
11
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
12
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
13
Everolimus Approved Phase 2 159351-69-6 6442177
14
Lenograstim Approved Phase 2 135968-09-1
15
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
16
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
17
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
18
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
19 Pomalidomide Approved Phase 1, Phase 2 19171-19-8
20
Doxil Approved June 1999 Phase 2,Phase 1 31703
21 Analgesics Phase 2
22 Antibodies Phase 2,Phase 1,Early Phase 1
23 Antibodies, Monoclonal Phase 2,Phase 1,Early Phase 1
24 Antipyretics Phase 2
25 Histamine Antagonists Phase 2
26 Histamine H1 Antagonists Phase 2
27 Immunoglobulins Phase 2,Phase 1,Early Phase 1
28 Alkylating Agents Phase 2,Phase 1
29 Angiogenesis Inhibitors Phase 2,Phase 1
30 Angiogenesis Modulating Agents Phase 2,Phase 1
31 Anti-Bacterial Agents Phase 2,Phase 1
32 Anti-Inflammatory Agents Phase 2,Phase 1
33 Antineoplastic Agents, Hormonal Phase 2,Phase 1
34 Antirheumatic Agents Phase 2,Phase 1
35 glucocorticoids Phase 2,Phase 1
36 Hormone Antagonists Phase 2,Phase 1
37 Hormones Phase 2,Phase 1
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
39 Immunosuppressive Agents Phase 2,Phase 1
40 Anti-HIV Agents Phase 2
41 Antimetabolites Phase 2
42 Anti-Retroviral Agents Phase 2
43 Nucleic Acid Synthesis Inhibitors Phase 2
44 Reverse Transcriptase Inhibitors Phase 2
45 Adjuvants, Immunologic Phase 2
46 Antibiotics, Antitubercular Phase 2,Phase 1
47 Antifungal Agents Phase 2
48 Antimitotic Agents Phase 2,Phase 1
49 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
50 Etoposide phosphate Phase 2,Phase 1

Interventional clinical trials:

(show all 19)

id Name Status NCT ID Phase Drugs
1 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4 Valganciclovir
2 A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease Completed NCT01024036 Phase 2 Siltuximab;Placebo;Best Supportive Care (BSC)
3 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
4 TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Recruiting NCT03043105 Phase 2 Thalidomide, cyclophosphamide and prednisone
5 Tocilizumab for KSHV-Associated Multicentric Castleman Disease Recruiting NCT01441063 Phase 2 Zidovudine;Tocilizumab;Valganciclovir (VGC)
6 Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Recruiting NCT00092222 Phase 2 Etoposide;Interferon-alpha;Rituximab;Zidovudine;Liposomal Doxorubicin;Bortezomib;Valganciclovir;Doxorubicin;Vincristine;Cyclophosphamide;Filgrastim (G-CSF);Prednisone;Sirolimus
7 Siltuximab in Schizophrenia Recruiting NCT02796859 Phase 1, Phase 2 Siltuximab;normal saline
8 A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Active, not recruiting NCT01400503 Phase 2 Siltuximab
9 Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy Terminated NCT00127569 Phase 2 Rituximab
10 Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Withdrawn NCT02228512 Phase 1, Phase 2 Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
11 A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment Completed NCT01183598 Phase 1 tocilizumab [RoActemra/Actemra]
12 Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma Recruiting NCT02659930 Phase 1 liposomal doxorubicin;pomalidomide
13 Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Terminated NCT02109224 Phase 1 Ibrutinib
14 Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials Completed NCT00695422
15 Unlock the Cell: Castleman's Disease Flow Cytometry Study Recruiting NCT02853968
16 Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer Recruiting NCT00006518
17 Castleman Disease Collaborative Network Biobank Recruiting NCT02871050
18 International Registry for Patients With Castleman Disease Recruiting NCT02817997
19 Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Withdrawn NCT02805868 Early Phase 1

Search NIH Clinical Center for Multicentric Castleman Disease

Genetic Tests for Multicentric Castleman Disease

Anatomical Context for Multicentric Castleman Disease

MalaCards organs/tissues related to Multicentric Castleman Disease:

39
Lymph Node, Liver, Spleen, B Cells, Bone, Bone Marrow, T Cells

Publications for Multicentric Castleman Disease

Articles related to Multicentric Castleman Disease:

(show top 50) (show all 143)
id Title Authors Year
1
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. ( 28087540 )
2017
2
Late-onset skin involvement on the forehead in multicentric Castleman disease. ( 28244070 )
2017
3
Thin-section Computed Tomographic Findings of Multicentric Castleman Disease Changing Over 10 Years. ( 28914746 )
2017
4
Multicentric Castleman disease: consensus at last? ( 28336727 )
2017
5
Corrigendum: Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. ( 28845155 )
2017
6
Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report. ( 28501028 )
2017
7
Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. ( 28143881 )
2017
8
TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease. ( 28135567 )
2017
9
TAFRO syndrome: An atypical variant of KSHV-negative multicentric Castleman disease. ( 26663467 )
2016
10
A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination. ( 26948831 )
2016
11
Bone marrow manifestations in multicentric Castleman disease. ( 26817834 )
2016
12
Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. ( 26805758 )
2016
13
iNKT and memory B cells alterations in HHV-8 multicentric Castleman disease. ( 28060720 )
2016
14
Case report and literature review: Glomerular and neurologic thrombotic microangiopathy as a primary manifestation of multicentric castleman disease. ( 27741115 )
2016
15
Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. ( 26980221 )
2016
16
Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related Multicentric Castleman disease. ( 27221364 )
2016
17
Multicentric Castleman disease: Where are we now? ( 27296355 )
2016
18
Unicentric versus Multicentric Castleman Disease. ( 27618317 )
2016
19
Human Herpesvirus Type 8-positive Multicentric Castleman Disease. ( 27133959 )
2016
20
Atypical presentation of multicentric Castleman disease in a pediatric patient: pleural and pericardial effusion. ( 26614115 )
2016
21
Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. ( 26634298 )
2016
22
(18)F-FDG PET/CT in multicentric Castleman disease: a case report. ( 26904580 )
2016
23
Multicentric Castleman Disease With Tubulointerstitial Nephritis Mimicking IgG4-related Disease: Two Case Reports. ( 26598921 )
2016
24
Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy. ( 25900626 )
2015
25
18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters. ( 25828248 )
2015
26
KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies. ( 24771491 )
2015
27
Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome. ( 25093377 )
2015
28
Budd-Chiari syndrome, a rare complication of multicentric Castleman disease: A case report. ( 26137030 )
2015
29
Tocilizumab for AA Amyloidosis after Treatment of Multicentric Castleman Disease with Steroids, Chemotherapy and Rituximab for Over 20 Years. ( 26666616 )
2015
30
FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. ( 25601959 )
2015
31
(Multicentric Castleman Disease with Monoclonal Incomplete IgH Restriction: A Rare Coexistence). ( 26490523 )
2015
32
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. ( 26124203 )
2015
33
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. ( 26327301 )
2015
34
Leukemic phase of a large B-cell lymphoma arising in KSHV-associated multicentric Castleman disease. ( 26756053 )
2015
35
Siltuximab for Multicentric Castleman Disease-Letter. ( 26473194 )
2015
36
Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease. ( 25208471 )
2015
37
Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi. ( 26242311 )
2015
38
Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease. ( 26394632 )
2015
39
Multicentric Castleman disease presenting with fever. ( 25282064 )
2014
40
Bone Marrow Involvement in Multicentric Castleman Disease in a HIV Negative Patient. ( 25332537 )
2014
41
Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. ( 24387011 )
2014
42
Successful single-lung transplantation for multicentric Castleman disease. ( 25193223 )
2014
43
HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. ( 24622327 )
2014
44
Multicentric Castleman disease mimicking IgG4-related disease: A case report. ( 25528859 )
2014
45
Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. ( 25331113 )
2014
46
Siltuximab for multicentric Castleman disease. ( 25110138 )
2014
47
Parsonage-Turner syndrome during the treatment of HIV/HHV8-related multicentric Castleman disease. ( 24365755 )
2013
48
Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenance. ( 24019247 )
2013
49
Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. ( 24174627 )
2013
50
Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. ( 24319170 )
2013

Variations for Multicentric Castleman Disease

Expression for Multicentric Castleman Disease

Search GEO for disease gene expression data for Multicentric Castleman Disease.

Pathways for Multicentric Castleman Disease

Pathways related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 32)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.59 ABCB1 IFNG IL10 IL21 IL5 IL6
2
Show member pathways
12.48 IFNG IL10 IL21 IL5 IL6
3 12.44 BCL6 IFNG IL10 PAX5
4
Show member pathways
12.32 IFNG IL10 IL5 IL6
5
Show member pathways
12.01 IFNG IL10 IL5 IL6
6
Show member pathways
11.89 IFNG IL10 IL21 IL5 IL6
7 11.88 BCL6 IL10 IL6
8 11.83 IFNG IL10 IL5 IL6
9
Show member pathways
11.81 IFNG IL21 IL6
10 11.8 IFNG IL10 IL6
11 11.78 IFNG IL10 IL21 IL6
12 11.73 CCL4 IFNG IL6
13
Show member pathways
11.73 IFNG IL10 IL21 IL6
14 11.71 IFNG IL5 IL6
15 11.68 IFNG IL10 IL5
16 11.66 IFNG IL10 IL6
17 11.57 BCL6 IL10 IL5
18 11.56 CCL4 IL5 IL6
19 11.44 CCL4 IL10 IL6
20 11.43 IFNG IL10 IL6
21 11.41 IFNG IL10 IL5
22
Show member pathways
11.3 CCL4 IFNG IL10
23 11.23 IFNG IL10 IL6
24 11.18 BCL6 IL10 IL21 PAX5
25 11.16 IFNG IL5 IL6
26 11.02 IFNG IL10 IL5
27 10.95 CCL4 IL10 IL21 IL5 IL6
28 10.95 BCL6 IL10 IL21 IL5 IL6 PAX5
29 10.93 CRP IL6
30 10.85 ID1 PAX5
31 10.81 IL5 IL6
32 10.73 IFNG IL10 IL5 IL6

GO Terms for Multicentric Castleman Disease

Cellular components related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CCL4 CRP F3 F8 IFNG IL10
2 extracellular space GO:0005615 9.28 CCL4 CRP F3 F8 IFNG IL10

Biological processes related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 CRP ID1 IFNG IL6
2 response to drug GO:0042493 9.87 ABCB1 IFNG IL10 IL6
3 cellular response to lipopolysaccharide GO:0071222 9.77 IFNG IL10 IL6
4 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.75 IL10 IL5 IL6
5 positive regulation of neuron differentiation GO:0045666 9.7 BCL6 IFNG IL6
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 IFNG IL21 IL6
7 positive regulation of T cell proliferation GO:0042102 9.63 IFNG IL21 IL6
8 positive regulation of JAK-STAT cascade GO:0046427 9.6 IL5 IL6
9 negative regulation of growth of symbiont in host GO:0044130 9.58 IFNG IL10
10 humoral immune response GO:0006959 9.58 IFNG IL6 PAX5
11 cellular response to hepatocyte growth factor stimulus GO:0035729 9.56 IL10 IL6
12 positive regulation of immunoglobulin secretion GO:0051024 9.55 IL5 IL6
13 positive regulation of protein import into nucleus, translocation GO:0033160 9.54 IFNG IL6
14 positive regulation of B cell proliferation GO:0030890 9.54 BCL6 IL21 IL5
15 negative regulation of lipid storage GO:0010888 9.51 CRP IL6
16 positive regulation of MHC class II biosynthetic process GO:0045348 9.49 IFNG IL10
17 type 2 immune response GO:0042092 9.43 BCL6 IL10
18 acute-phase response GO:0006953 9.43 CRP F8 IL6
19 immune response GO:0006955 9.43 CCL4 IFNG IL10 IL21 IL5 IL6
20 defense response to protozoan GO:0042832 9.33 IFNG IL10 IL6
21 neutrophil apoptotic process GO:0001781 9.32 IFNG IL6
22 inflammatory response GO:0006954 9.1 BCL6 CCL4 CRP IL10 IL5 IL6

Molecular functions related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 CCL4 IFNG IL10 IL21 IL5 IL6

Sources for Multicentric Castleman Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....